Physician profile
Michael G Gibson
NPI 1013068881
$7,911.41
in general payments reported to CMS, 2019-2025
57 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $912 · 2021: $986 · 2022: $1,506 · 2023: $961 · 2024: $956 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $689.77 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbott Laboratories | $665.05 | 2019-2025 | Proclaim |
| Collegium Pharmaceutical, INC. | $643.85 | 2019-2025 | Belbuca, Xtampza |
| Pfizer INC. | $606.76 | 2019-2025 | |
| Forte Bio-Pharma LLC | $561.45 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Nevro Corp. | $391.80 | 2019-2020 | |
| Abbvie INC. | $390.79 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $321.62 | 2019-2024 | Ztlido |
| Spr Therapeutics, INC | $256.41 | 2024-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.76 | 2019-2025 | Relistor |
| Merck Sharp & Dohme LLC | $227.42 | 2021-2023 | Belsomra |
| Biotronik Nro, INC. | $203.91 | 2025 | Prospera |
| Amgen INC. | $176.60 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.14 | 2022 | |
| Grt US Holding, INC. | $139.87 | 2020-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.